Versartis, Inc – OTCQB: VSAR
Shares of Versartis, Inc. are moving higher in early trading on heavy volume. The Menlo, CA-based company trades on the Nasdaq under ticker symbol VSAR. Versartis is an endocrine-focused biopharmaceutical company that is developing a form of recombinant human growth hormone to treat growth hormone deficiency (GHD) in children and adults.
Unconfirmed reports suggest that Versartis, Inc has filed a “Confidential Treatment Report” with the SEC. Such a filing would allow for information in an SEC filing to be kept secret, if leaking such information could cause material or financial harm to the company or a business partner.
Shares of VSAR closed yesterday at $13.30 and are trading at $15.10 at 11:22 EST. Volumes are heavy and trader chat rooms are active. According to information gathered from the Nasdaq website, four firms follow VSAR – one rating it as a “Hold” and three giving it a “Strong Buy”. The consensus price target is $23.50.
Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. All information or data is provided without any guarantee of its accuracy.
|Last Price a/o 11:27 EST||$ 14.85|
|Shares Outstanding||35.33 million|
|Share Float||34.57 million|
|Short Interest Ratio||4.64|